TyRx surgical mesh
This article was originally published in Clinica
Executive Summary
TyRx Pharma has received US FDA 510(k) clearance for its bioresorbable polymer-coated surgical mesh for repairing hernias and other abdominal fascial or muscular deficiencies that require a reinforcing material to improve surgical results. The product incorporates features that the firm believes will help alleviate some of the problems associated with the use of synthetic mesh implants. It has handling characteristics that facilitate its precise placement during a surgical repair and leave less implant material following the resorption of the bioresorbable polymer coating. Less implant material should help facilitate patient comfort during the post-operative period and beyond, said the Monmouth, Junction, New Jersey firm. The mesh is scheduled for launch in the first quarter of this year.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.